Laidlaw Initiates Coverage on Novogen (NASDAQ:KZIA)

Equities researchers at Laidlaw initiated coverage on shares of Novogen (NASDAQ:KZIA) in a note issued to investors on Wednesday, Marketbeat.com reports. The brokerage set a “buy” rating and a $25.00 price target on the stock. Laidlaw’s target price points to a potential upside of 128.94% from the company’s previous close.

Several other research firms also recently commented on KZIA. HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of Novogen in a report on Wednesday, January 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Novogen in a report on Thursday, January 22nd. Finally, Wall Street Zen downgraded Novogen from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.00.

Novogen Stock Up 9.2%

NASDAQ:KZIA opened at $10.92 on Wednesday. Novogen has a twelve month low of $2.86 and a twelve month high of $17.40. The business has a 50 day moving average price of $7.55 and a two-hundred day moving average price of $7.83.

Novogen (NASDAQ:KZIA) last released its quarterly earnings data on Saturday, February 14th. The company reported ($1.34) EPS for the quarter. The firm had revenue of $4.89 million during the quarter.

Novogen Company Profile

Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.